The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Synopsis
Daptomycin is a lipopeptide antibiotic used in the treatment of systemic and life-threatening infections caused by Gram-positive organisms.
The global Daptomycin market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Daptomycin is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Daptomycin is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Daptomycin include Merck & Co., Pfizer, Teva, Mylan, Fresenius Kabi, Sagent Pharmaceuticals, Xellia, Hisun and HENGRUI PHARMA, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Daptomycin, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Daptomycin.
Report Scope
The Daptomycin market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Daptomycin market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Daptomycin manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Merck & Co.
Pfizer
Teva
Mylan
Fresenius Kabi
Sagent Pharmaceuticals
Xellia
Hisun
HENGRUI PHARMA
Huadong Medicine
Segment by Type
350 mg Lyophilized Powder
500 mg Lyophilized Powder
Segment by Application
Adult
Pediatric Patients (1 to 17 years of age)
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Daptomycin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Daptomycin in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Daptomycin is a lipopeptide antibiotic used in the treatment of systemic and life-threatening infections caused by Gram-positive organisms.
The global Daptomycin market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Daptomycin is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Daptomycin is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Daptomycin include Merck & Co., Pfizer, Teva, Mylan, Fresenius Kabi, Sagent Pharmaceuticals, Xellia, Hisun and HENGRUI PHARMA, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Daptomycin, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Daptomycin.
Report Scope
The Daptomycin market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Daptomycin market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Daptomycin manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Merck & Co.
Pfizer
Teva
Mylan
Fresenius Kabi
Sagent Pharmaceuticals
Xellia
Hisun
HENGRUI PHARMA
Huadong Medicine
Segment by Type
350 mg Lyophilized Powder
500 mg Lyophilized Powder
Segment by Application
Adult
Pediatric Patients (1 to 17 years of age)
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Daptomycin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Daptomycin in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Daptomycin Market Overview
1.1 Product Overview and Scope of Daptomycin
1.2 Daptomycin Segment by Type
1.2.1 Global Daptomycin Market Value Comparison by Type (2024-2030)
1.2.2 350 mg Lyophilized Powder
1.2.3 500 mg Lyophilized Powder
1.3 Daptomycin Segment by Application
1.3.1 Global Daptomycin Market Value by Application: (2024-2030)
1.3.2 Adult
1.3.3 Pediatric Patients (1 to 17 years of age)
1.4 Global Daptomycin Market Size Estimates and Forecasts
1.4.1 Global Daptomycin Revenue 2019-2030
1.4.2 Global Daptomycin Sales 2019-2030
1.4.3 Global Daptomycin Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Daptomycin Market Competition by Manufacturers
2.1 Global Daptomycin Sales Market Share by Manufacturers (2019-2024)
2.2 Global Daptomycin Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Daptomycin Average Price by Manufacturers (2019-2024)
2.4 Global Daptomycin Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Daptomycin, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Daptomycin, Product Type & Application
2.7 Daptomycin Market Competitive Situation and Trends
2.7.1 Daptomycin Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Daptomycin Players Market Share by Revenue
2.7.3 Global Daptomycin Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Daptomycin Retrospective Market Scenario by Region
3.1 Global Daptomycin Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Daptomycin Global Daptomycin Sales by Region: 2019-2030
3.2.1 Global Daptomycin Sales by Region: 2019-2024
3.2.2 Global Daptomycin Sales by Region: 2025-2030
3.3 Global Daptomycin Global Daptomycin Revenue by Region: 2019-2030
3.3.1 Global Daptomycin Revenue by Region: 2019-2024
3.3.2 Global Daptomycin Revenue by Region: 2025-2030
3.4 North America Daptomycin Market Facts & Figures by Country
3.4.1 North America Daptomycin Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Daptomycin Sales by Country (2019-2030)
3.4.3 North America Daptomycin Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Daptomycin Market Facts & Figures by Country
3.5.1 Europe Daptomycin Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Daptomycin Sales by Country (2019-2030)
3.5.3 Europe Daptomycin Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Daptomycin Market Facts & Figures by Country
3.6.1 Asia Pacific Daptomycin Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Daptomycin Sales by Country (2019-2030)
3.6.3 Asia Pacific Daptomycin Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Daptomycin Market Facts & Figures by Country
3.7.1 Latin America Daptomycin Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Daptomycin Sales by Country (2019-2030)
3.7.3 Latin America Daptomycin Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Daptomycin Market Facts & Figures by Country
3.8.1 Middle East and Africa Daptomycin Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Daptomycin Sales by Country (2019-2030)
3.8.3 Middle East and Africa Daptomycin Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Daptomycin Sales by Type (2019-2030)
4.1.1 Global Daptomycin Sales by Type (2019-2024)
4.1.2 Global Daptomycin Sales by Type (2025-2030)
4.1.3 Global Daptomycin Sales Market Share by Type (2019-2030)
4.2 Global Daptomycin Revenue by Type (2019-2030)
4.2.1 Global Daptomycin Revenue by Type (2019-2024)
4.2.2 Global Daptomycin Revenue by Type (2025-2030)
4.2.3 Global Daptomycin Revenue Market Share by Type (2019-2030)
4.3 Global Daptomycin Price by Type (2019-2030)
5 Segment by Application
5.1 Global Daptomycin Sales by Application (2019-2030)
5.1.1 Global Daptomycin Sales by Application (2019-2024)
5.1.2 Global Daptomycin Sales by Application (2025-2030)
5.1.3 Global Daptomycin Sales Market Share by Application (2019-2030)
5.2 Global Daptomycin Revenue by Application (2019-2030)
5.2.1 Global Daptomycin Revenue by Application (2019-2024)
5.2.2 Global Daptomycin Revenue by Application (2025-2030)
5.2.3 Global Daptomycin Revenue Market Share by Application (2019-2030)
5.3 Global Daptomycin Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Merck & Co.
6.1.1 Merck & Co. Corporation Information
6.1.2 Merck & Co. Description and Business Overview
6.1.3 Merck & Co. Daptomycin Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Merck & Co. Daptomycin Product Portfolio
6.1.5 Merck & Co. Recent Developments/Updates
6.2 Pfizer
6.2.1 Pfizer Corporation Information
6.2.2 Pfizer Description and Business Overview
6.2.3 Pfizer Daptomycin Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Pfizer Daptomycin Product Portfolio
6.2.5 Pfizer Recent Developments/Updates
6.3 Teva
6.3.1 Teva Corporation Information
6.3.2 Teva Description and Business Overview
6.3.3 Teva Daptomycin Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Teva Daptomycin Product Portfolio
6.3.5 Teva Recent Developments/Updates
6.4 Mylan
6.4.1 Mylan Corporation Information
6.4.2 Mylan Description and Business Overview
6.4.3 Mylan Daptomycin Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Mylan Daptomycin Product Portfolio
6.4.5 Mylan Recent Developments/Updates
6.5 Fresenius Kabi
6.5.1 Fresenius Kabi Corporation Information
6.5.2 Fresenius Kabi Description and Business Overview
6.5.3 Fresenius Kabi Daptomycin Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Fresenius Kabi Daptomycin Product Portfolio
6.5.5 Fresenius Kabi Recent Developments/Updates
6.6 Sagent Pharmaceuticals
6.6.1 Sagent Pharmaceuticals Corporation Information
6.6.2 Sagent Pharmaceuticals Description and Business Overview
6.6.3 Sagent Pharmaceuticals Daptomycin Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Sagent Pharmaceuticals Daptomycin Product Portfolio
6.6.5 Sagent Pharmaceuticals Recent Developments/Updates
6.7 Xellia
6.6.1 Xellia Corporation Information
6.6.2 Xellia Description and Business Overview
6.6.3 Xellia Daptomycin Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Xellia Daptomycin Product Portfolio
6.7.5 Xellia Recent Developments/Updates
6.8 Hisun
6.8.1 Hisun Corporation Information
6.8.2 Hisun Description and Business Overview
6.8.3 Hisun Daptomycin Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Hisun Daptomycin Product Portfolio
6.8.5 Hisun Recent Developments/Updates
6.9 HENGRUI PHARMA
6.9.1 HENGRUI PHARMA Corporation Information
6.9.2 HENGRUI PHARMA Description and Business Overview
6.9.3 HENGRUI PHARMA Daptomycin Sales, Revenue and Gross Margin (2019-2024)
6.9.4 HENGRUI PHARMA Daptomycin Product Portfolio
6.9.5 HENGRUI PHARMA Recent Developments/Updates
6.10 Huadong Medicine
6.10.1 Huadong Medicine Corporation Information
6.10.2 Huadong Medicine Description and Business Overview
6.10.3 Huadong Medicine Daptomycin Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Huadong Medicine Daptomycin Product Portfolio
6.10.5 Huadong Medicine Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Daptomycin Industry Chain Analysis
7.2 Daptomycin Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Daptomycin Production Mode & Process
7.4 Daptomycin Sales and Marketing
7.4.1 Daptomycin Sales Channels
7.4.2 Daptomycin Distributors
7.5 Daptomycin Customers
8 Daptomycin Market Dynamics
8.1 Daptomycin Industry Trends
8.2 Daptomycin Market Drivers
8.3 Daptomycin Market Challenges
8.4 Daptomycin Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
